The Conflict of Evidence

This flow traces how observational data, registries, and small clinical series produce competing interpretations of HCV management.

increasingBearing stren­gth in each eventdecreasing

Promising Small Studies

Promising Small Studies Signals of benefit Small cohorts report improved proteinuria, viral clearance, or liver enzymes after antiviral and immunologic treatments. These findings encourage therapeutic action. Fragile foundations The studies are often uncontrolled, contain few patients, and use changing doses. Their promise is real but cannot settle the safety question.

Registry Contradictions

Registry Contradictions Population-scale warning Registry studies associate HCV with poorer patient and graft survival, but recipients of HCV-positive donor kidneys may also be older, sicker, or more immunologically complex. Confounding exposed The conflict is not simply between true and false results. It concerns whether observed outcomes belong to HCV itself, the patient’s baseline risk, or the treatment environment.

Guideline Moderation

Guideline Moderation From certainty to conditional advice Guidelines favor screening, staging, infection control, and pretransplant treatment while acknowledging limited randomized evidence. Recommendations become graded and context dependent. Practical resolution Clinical judgment is not eliminated by evidence; it is disciplined by it. The book’s final posture is cautious action under acknowledged uncertainty.

1990s to early 2000s

2000s

2008 to 2012